These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16273354)

  • 1. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer.
    Gleave M; Miyake H; Chi K
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():47-57. PubMed ID: 16273354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent androgen suppression for prostate cancer: rationale and clinical experience.
    Gleave M; Goldenberg SL; Bruchovsky N; Rennie P
    Prostate Cancer Prostatic Dis; 1998 Dec; 1(6):289-296. PubMed ID: 12496869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
    Miyake H; Hara I; Gleave ME
    Int J Urol; 2005 Sep; 12(9):785-94. PubMed ID: 16201973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
    Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
    Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors.
    Kiyama S; Morrison K; Zellweger T; Akbari M; Cox M; Yu D; Miyake H; Gleave ME
    Cancer Res; 2003 Jul; 63(13):3575-84. PubMed ID: 12839944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.
    Andrieu C; Taieb D; Baylot V; Ettinger S; Soubeyran P; De-Thonel A; Nelson C; Garrido C; So A; Fazli L; Bladou F; Gleave M; Iovanna JL; Rocchi P
    Oncogene; 2010 Apr; 29(13):1883-96. PubMed ID: 20101233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
    Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.
    Miyake H; Tolcher A; Gleave ME
    Cancer Res; 1999 Aug; 59(16):4030-4. PubMed ID: 10463603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer.
    Miyake H; Nelson C; Rennie PS; Gleave ME
    Cancer Res; 2000 Jan; 60(1):170-6. PubMed ID: 10646870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
    Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
    Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined use of antisense oligonucleotides and chemotherapeutics in the treatment of refractory prostate cancer.
    Baltogiannis D; Charalabopoulos K; Giannakopoulos X; Karakosta A; Sofikitis N
    Exp Oncol; 2005 Jun; 27(2):91-3. PubMed ID: 15995623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro.
    Rocchi P; Jugpal P; So A; Sinneman S; Ettinger S; Fazli L; Nelson C; Gleave M
    BJU Int; 2006 Nov; 98(5):1082-9. PubMed ID: 16879439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.
    Gleave ME; Miyake H; Zellweger T; Chi K; July L; Nelson C; Rennie P
    Urology; 2001 Aug; 58(2 Suppl 1):39-49. PubMed ID: 11502446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers.
    Gleave M; Chi KN
    Ann N Y Acad Sci; 2005 Nov; 1058():1-15. PubMed ID: 16394121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clusterin is not essential for androgen-regulated involution and regeneration of the normal mouse prostate.
    Fink D; Fazli L; Aronow B; Gleave ME; Ong CJ
    Prostate; 2006 Sep; 66(13):1445-54. PubMed ID: 16865725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent Androgen Suppression as a Treatment for Prostate Cancer: A Review.
    Evens AM; Lestingi TM; Bitran JD
    Oncologist; 1998; 3(6):419-423. PubMed ID: 10388133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer: status of current treatments and emerging antisense-based therapies.
    Devi GR
    Curr Opin Mol Ther; 2002 Apr; 4(2):138-48. PubMed ID: 12044035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bad expression influences time to androgen escape in prostate cancer.
    Teo K; Gemmell L; Mukherjee R; Traynor P; Edwards J
    BJU Int; 2007 Sep; 100(3):691-6. PubMed ID: 17542986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage.
    Lin Y; Fukuchi J; Hiipakka RA; Kokontis JM; Xiang J
    Cell Res; 2007 Jun; 17(6):531-6. PubMed ID: 17404601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
    Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
    BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.